Q-Line Biotech Limited (NSE:QLINE)

India · Delayed Price · Currency is INR

531.40

-6.45 (-1.20%)

At close: Jul 20, 2026

54.93% (1Y)

Market Cap	12.40B
Revenue (ttm)	3.47B +14.2%
Net Income	557.22M +1.3%
EPS	34.79 -5.1%
Shares Out	23.33M
PE Ratio	15.27
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	78,000
Open	537.00
Previous Close	537.85
Day's Range	525.00 - 546.50
52-Week Range	343.00 - 600.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 16, 2026

About Q-Line Biotech

Q-Line Biotech Limited develops, manufactures, and markets various reagents and consumables in India and internationally. It offers reagent kits, rapid cards, consumables, and point-of-care strips for applications in immunodiagnostics, hematology, molecular diagnostics, clinical chemistry, and others, as well as in vitro testing of human samples, supporting disease prediction, prevention, diagnosis, monitoring, and health status evaluation. The company also provides diagnostic equipment comprising analyzers, point-of-care devices, and other cri... [Read more]

Industry In Vitro and In Vivo Diagnostic Substances

Founded 2010

Employees 313

Stock Exchange National Stock Exchange of India

Ticker Symbol QLINE

Full Company Profile

Financial Performance

In fiscal year 2026, Q-Line Biotech's revenue was 3.47 billion, an increase of 10.73% compared to the previous year's 3.14 billion. Earnings were 557.22 million, an increase of 23.56%.

Financial Statements